United States - English - NLM (National Library of Medicine)

ascend laboratories, llc - cefixime (unii: 97i1c92e55) (cefixime anhydrous - unii:xz7bg04gjx) - cefixime is indicated in the treatment of adults and pediatric patients six months of age or older with uncomplicated urinary tract infections caused by susceptible isolates of escherichia coli and proteus mirabilis . cefixime capsules are indicated in the treatment of adults and pediatric patients six months of age or older with pharyngitis and tonsillitis caused by susceptible isolates of streptococcus pyogenes. (note: penicillin is the usual drug of choice in the treatment of streptococcus pyogenes infections. cefixime capsules are generally effective in the eradication of streptococcus pyogenes from the nasopharynx; however, data establishing the efficacy of cefixime capsules in the subsequent prevention of rheumatic fever is not available.) cefixime capsules is indicated in the treatment of adults and pediatric patients six months of age or older with acute exacerbations of chronic bronchitis caused by susceptible isolates of streptococcus pneumoniae and haemophilus influenzae. cefixime capsules is

United States - English - NLM (National Library of Medicine)

belcher pharmaceuticals,llc - cefixime (unii: 97i1c92e55) (cefixime anhydrous - unii:xz7bg04gjx) - to reduce the development of drug resistant bacteria and maintain the effectiveness of cefixime for oral suspension and other antibacterial drugs, cefixime for oral suspension should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antimicrobial therapy. in the absence of such data,local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. cefixime for oral suspension is a cephalosporin antibacterial drug indicated in the treatment of adults and pediatric patients six months of age or older with the following infections when caused by susceptible isolates of the designated bacteria: uncomplicated urinary tract infections caused by escherichia coli and proteus mirabilis otitis media caused by haemophilus influenzae, moraxella catarrhalis, and streptococcus pyogenes. (efficacy for streptococcus py

Kenya - English - Pharmacy and Poisons Board

riva pharma s.a.e free zone nasr city cairo egypt - cefixime trihydrate e. to cefixime - powder for oral suspension - cefixime trihydrate 111.92mg eq. to cefixime… - cefixime

United States - English - NLM (National Library of Medicine)

lupin pharma - cefixime (unii: 97i1c92e55) (cefixime anhydrous - unii:xz7bg04gjx) - cefixime anhydrous 100 mg - to reduce the development of drug resistant bacteria and maintain the effectiveness of suprax (cefixime) chewable tablets and other antibacterial drugs, suprax (cefixime) chewable tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antimicrobial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. suprax (cefixime) chewable tablets are indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: uncomplicated urinary tract infections caused by escherichia coli and proteus mirabilis . otitis media caused by haemophilus influenzae (beta-lactamase positive and negative strains), moraxella (branhamella) catarrhalis , (most of which are beta-lactamase positive) and s. pyogene

United States - English - NLM (National Library of Medicine)

health department, oklahoma state - cefixime (unii: 97i1c92e55) (cefixime anhydrous - unii:xz7bg04gjx) -

Kenya - English - Pharmacy and Poisons Board

oriana limited p.o box 19528-00202, nairobi - cefixime trihydrate usp equiv. to cefixime and… - suspension and effervescent granules for oral - cefixime trihydrate usp equiv. to cefixime 50.00… - cefixime

Kenya - English - Pharmacy and Poisons Board

square pharmaceuticals ltd. square centre, 48, mohakhali c.a, dhaka – 1212. - cefixime as cefixime trihydrate (micronized) - powder for oral solution - cefixime 200 mg / 5 ml as cefixime trihydrate usp… - cefixime

Kenya - English - Pharmacy and Poisons Board

riva pharma s.a.e free zone nasr city cairo egypt - cefixime trihydrate eq. to cefixime - capsule - cefixime trihydrate 477.63mg eq. to cefixime 400mg - cefixime

United States - English - NLM (National Library of Medicine)

lupin limited - cefixime (unii: 97i1c92e55) (cefixime anhydrous - unii:xz7bg04gjx) - cefixime anhydrous 400 mg

United States - English - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - cefixime (unii: 97i1c92e55) (cefixime anhydrous - unii:xz7bg04gjx) - cefixime anhydrous 400 mg - suprax is indicated in the treatment of adults and pediatric patients six months of age or older with uncomplicated urinary tract infections caused by susceptible isolates of escherichia coli and proteus mirabilis . suprax is indicated in the treatment of adults and pediatric patients six months of age or older with otitis media caused by susceptible isolates of haemophilus influenzae , moraxella catarrhalis , and streptococcus pyogenes. (efficacy for streptococcus pyogenes in this organ system was studied in fewer than 10 infections.) note: for patients with otitis media caused by streptococcus pneumoniae , overall response was approximately 10% lower for cefixime than for the comparator [see clinical studies ( 14)]. suprax is indicated in the treatment of adults and pediatric patients six months of age or older with pharyngitis and tonsillitis caused by susceptible isol